711 related articles for article (PubMed ID: 16637795)
21. Bisphosphonate treatment recommendations for oncologists.
von Moos R
Oncologist; 2005; 10 Suppl 1():19-24. PubMed ID: 16264109
[TBL] [Abstract][Full Text] [Related]
22. Bisphosphonates for cancer patients: why, how, and when?
Body JJ; Mancini I
Support Care Cancer; 2002 Jul; 10(5):399-407. PubMed ID: 12136223
[TBL] [Abstract][Full Text] [Related]
23. Tolerability of different dosing regimens of bisphosphonates for the treatment of osteoporosis and malignant bone disease.
Bobba RS; Beattie K; Parkinson B; Kumbhare D; Adachi JD
Drug Saf; 2006; 29(12):1133-52. PubMed ID: 17147460
[TBL] [Abstract][Full Text] [Related]
24. Beyond daily dosing: clinical experience.
Cooper C
Bone; 2006 Apr; 38(4 Suppl 1):S13-7. PubMed ID: 16520105
[TBL] [Abstract][Full Text] [Related]
25. [Therapeutic agents for disorders of bone and calcium metabolism: Zoledronic acid].
Sakurai T
Clin Calcium; 2007 Jan; 17(1):24-8. PubMed ID: 17211090
[TBL] [Abstract][Full Text] [Related]
26. Bisphosphonates for malignancy-related bone disease: current status, future developments.
Body JJ
Support Care Cancer; 2006 May; 14(5):408-18. PubMed ID: 16450087
[TBL] [Abstract][Full Text] [Related]
27. Zoledronic acid: a new parenteral bisphosphonate.
Li EC; Davis LE
Clin Ther; 2003 Nov; 25(11):2669-708. PubMed ID: 14693298
[TBL] [Abstract][Full Text] [Related]
28. Safety and efficacy of the new bisphosphonate ibandronate in the management of bone metastasis following rapid infusion.
Syrigos KN; Michalaki V; Mitromaras A; Pliarchopoulou F; Katirtzoglou N; Antonaki E; Roussou P
In Vivo; 2002; 16(5):361-3. PubMed ID: 12494878
[TBL] [Abstract][Full Text] [Related]
29. [Current use of bisphosphonates in clinical oncology].
Vrbanec D; Plestina S; Belev B; Unusić J; Pavlinić-Diminić V
Lijec Vjesn; 1999; 121(9-10):296-301. PubMed ID: 19658372
[TBL] [Abstract][Full Text] [Related]
30. Effects of ibandronate on bone quality: preclinical studies.
Bauss F; Dempster DW
Bone; 2007 Feb; 40(2):265-73. PubMed ID: 16996333
[TBL] [Abstract][Full Text] [Related]
31. Bisphosphonates--role in cancer therapies.
Mehrotra B
J Oral Maxillofac Surg; 2009 May; 67(5 Suppl):19-26. PubMed ID: 19371811
[No Abstract] [Full Text] [Related]
32. Effects of intravenous ibandronate injection on renal function in women with postmenopausal osteoporosis at high risk for renal disease--the DIVINE study.
Miller PD; Ragi-Eis S; Mautalen C; Ramirez F; Jonkanski I
Bone; 2011 Dec; 49(6):1317-22. PubMed ID: 21945737
[TBL] [Abstract][Full Text] [Related]
33. Quarterly intravenous injection of ibandronate to treat osteoporosis in postmenopausal women.
Sambrook P
Clin Interv Aging; 2007; 2(1):65-72. PubMed ID: 18044076
[TBL] [Abstract][Full Text] [Related]
34. Quarterly intravenous ibandronate for postmenopausal osteoporosis.
Emkey RD
Womens Health (Lond); 2008 May; 4(3):219-28. PubMed ID: 19072470
[TBL] [Abstract][Full Text] [Related]
35. Safety of intravenous and oral bisphosphonates and compliance with dosing regimens.
Conte P; Guarneri V
Oncologist; 2004; 9 Suppl 4():28-37. PubMed ID: 15459427
[TBL] [Abstract][Full Text] [Related]
36. Safety and convenience of a 15-minute infusion of zoledronic acid.
Berenson J; Hirschberg R
Oncologist; 2004; 9(3):319-29. PubMed ID: 15169987
[TBL] [Abstract][Full Text] [Related]
37. Role of bisphosphonates in prevention and treatment of bone metastases from breast cancer.
Paterson AH; Kanis JA; Powles TJ; McCloskey E; Hanson J; Ashley S
Can J Oncol; 1995 Dec; 5 Suppl 1():54-7. PubMed ID: 8853526
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study.
Eisman JA; Civitelli R; Adami S; Czerwinski E; Recknor C; Prince R; Reginster JY; Zaidi M; Felsenberg D; Hughes C; Mairon N; Masanauskaite D; Reid DM; Delmas PD; Recker RR
J Rheumatol; 2008 Mar; 35(3):488-97. PubMed ID: 18260172
[TBL] [Abstract][Full Text] [Related]
39. [Biphosphonate therapy in the management of skeletal metastases].
Grauer A; Ziegler R
Orthopade; 1998 Apr; 27(4):231-9. PubMed ID: 9616882
[TBL] [Abstract][Full Text] [Related]
40. Effect of daily and intermittent use of ibandronate on bone mass and bone turnover in postmenopausal osteoporosis: a review of three phase II studies.
Schimmer RC; Bauss F
Clin Ther; 2003 Jan; 25(1):19-34. PubMed ID: 12637110
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
